Asian Multicenter Prospective Study in HER2 Positive Early Breast Cancer for Detecting MRD by ctDNA;HARMONY Study

Recruiting now

Conditions studied: HER2-positive Breast Cancer

In brief

This study will assess minimal residual disease (MRD) in HER2-positive early breast cancer patients in Asian countries. The purpose is to evaluate the relation between the detection rate of MRD and recurrence.

Key facts

Study ID

NCT05433753

Run by

National Cancer Center, Japan

People needed

60

Starts

2022-05-24

Expected to finish

2027-09-30

Last updated by the study team

2024-03-25

Who can join

Age: 20 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age of 20 years or older at the date of registration.
• Histological diagnosis of HER2-positive invasive breast carcinoma.
• Patients scheduled for neoadjuvant chemotherapy followed by surgery.
• Clinical Stage IIA-IIIC.
• Known hormone receptor status.
• Signed informed consent.

You may not qualify if…

• Any other malignancy within 5 years prior to registration, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the esophagus, stomach, colon, or cervix.
• Bilateral synchronous breast cancer.
• History of breast cancer.
• Pregnancy at registration.

Where it is running

• National Cancer Center Hospital, Japan — Chuo-ku, Tokyo, Japan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.